MDMA: device tax will especially harm small companies; Philips Healthcare turns to India;

 @FierceMedDev: Renal denervation's not just for hypertension--docs say it could help diabetics, too. More | Follow @FierceMedDev

 @MarkHFierce: Ilex will sell Novartis' blood test Dx kits in 16 African countries. More | Follow @MarkHFierce

 @DamianFierce: According to a new study, women fare worse with stents than men. More | Follow @DamianFierce

> The impending medical device tax will be especially damaging to small, emerging companies whose profit margins can't sustain a 2.3% hit, according to the Medical Device Manufacturers Association. Story

> Medtronic ($MDT) is launching its Amphirion Plus percutaneous transluminal angioplasty catheter, aimed to relieve narrowing and blockage in below-the-knee arteries. Item

> Tactile Systems Technology, the Minnesota maker of a home lymphedema treatment device, pulled in $10.4 million in a Series B round of financing, MedCity News reports. Story

> Arrayit Diagnostics, maker of molecular cancer tests, pulled in $8 million in financing from the American Equity Fund. News

> Johnson & Johnson's ($JNJ) stock price could soar even higher based on the growth of its medical devices and pharma pipelines, an analyst writes in Forbes. Opinion

> California's Biolase got 510(k) clearance and a CE mark for its Epic 10 dental laser, designed to reduce patient pain in oral surgery. Article

> Cook Medical has launched the Zilver Vena self-expanding stent in Canada. The device is aimed to restore blood flow in obstructed iliofemoral veins. Release

> Philadelphia life sciences startup CytoVas will begin to test a new diagnostic to measure vascular health. Item

> Philips Healthcare ($PHG) is expanding its Indian marketing operations, looking to sell lower-cost devices to hospitals in need. More

Biotech News

 @FierceBiotech: Sanofi stands up for diabetes therapy in crowded GLP-1 contest. More | Follow @FierceBiotech

 @JohnCFierce: Anacor gets an antibiotic back from Glaxo after microbiological resistance was seen in a study. Worthless now. More | Follow @JohnCFierce

 @RyanMFierce: Takeda builds up new vaccine unit with $60M LigoCyte buyout, with interview quotes. Article | Follow @RyanMFierce

> Defining 'fierce' in the modern age of drug and device development. Editor's Corner

> The Medicines Co. abandons blood-loss drug over safety risk. More

Pharma News

@FiercePharma: Takeda continues buying spree, picks up LigoCyte. More | Follow @FiercePharma

@EricPFierce: Australia Mayne Pharma buying SC-based CDMO Metrics for $105 million plus milestone. More | Follow @EricPFierce

> J&J settles Risperdal cases, avoiding former FDA commish's testimony. Story

> NICE reverses position on new use for Novartis' Lucentis. More

 

Suggested Articles

J&J launched a virtual clinical study to gauge whether Apple’s iPhone and ECG-enabled smartwatch can help reduce the risk of stroke and catch AFib.

The Salt Lake City-based developer said its Logix Smart test is now available to be exported from Utah to countries requiring the CE Mark.

Dexcom received a new European approval for its wearable continuous glucose monitor in pregnant women across Type 1, Type 2 and gestational diabetes.